Comparative Pharmacology
Head-to-head clinical analysis: AVZIVI versus MACUGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVZIVI versus MACUGEN.
AVZIVI vs MACUGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avizivi (avelumab) is a human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 receptors. This restores anti-tumor immune responses, including T-cell activation and proliferation, by reversing PD-L1-mediated inhibition.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
IV 200 mg over 30 minutes on Day 1 of a 21-day cycle, in combination with paclitaxel and carboplatin; continue until disease progression or unacceptable toxicity.
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 h) in patients with normal renal function; prolonged to 24–48 h in moderate-to-severe renal impairment.
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
Primarily renal excretion as unchanged drug (~70%) and glucuronide conjugate (~30%); biliary/fecal excretion accounts for <5%.
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor